These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19022927)

  • 41. Peginterferon and ribavirin for hepatitis C.
    Evoli A; Servidei S
    N Engl J Med; 2007 Mar; 356(12):1269-70; author reply 1271. PubMed ID: 17380575
    [No Abstract]   [Full Text] [Related]  

  • 42. [Combination therapy for chronic viral hepatitis C].
    Zeuzem S
    Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
    [No Abstract]   [Full Text] [Related]  

  • 43. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 44. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin.
    Sykia A; Gigi E; Sinakos E; Bibashi E; Bellou A; Raptopoulou-Gigi M
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):118-9. PubMed ID: 19337648
    [No Abstract]   [Full Text] [Related]  

  • 45. [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
    Honsová E; Sticová E; Sperl J
    Cesk Patol; 2007 Jan; 43(1):27-30. PubMed ID: 17370474
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases.
    Lübbe J; Kerl K; Negro F; Saurat JH
    Br J Dermatol; 2005 Nov; 153(5):1088-90. PubMed ID: 16225644
    [No Abstract]   [Full Text] [Related]  

  • 47. The management of side-effects during therapy for hepatitis C.
    Aspinall RJ; Pockros PJ
    Aliment Pharmacol Ther; 2004 Nov; 20(9):917-29. PubMed ID: 15521838
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tolerability of Peg interferon-alpha2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency.
    Demelia L; Civolani A; Murgia D; Murru A; Sorbello O; Rizzetto M
    J Hepatol; 2007 Jan; 46(1):171-3. PubMed ID: 17107736
    [No Abstract]   [Full Text] [Related]  

  • 49. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 50. Interferon and ribavirin treatment for chronic hepatitis C may activate celiac disease.
    Adinolfi LE; Durante Mangoni E; Andreana A
    Am J Gastroenterol; 2001 Feb; 96(2):607-8. PubMed ID: 11232725
    [No Abstract]   [Full Text] [Related]  

  • 51. Onset of dermatitis herpetiformis after treatment by interferon and ribavirin for chronic hepatitis C.
    Borghi-Scoazec G; Merle P; Scoazec JY; Claudy A; Trepo C
    J Hepatol; 2004 May; 40(5):871-2. PubMed ID: 15094241
    [No Abstract]   [Full Text] [Related]  

  • 52. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection.
    Girard C; Bessis D; Blatìre V; Guilhou JJ; Guillot B
    Br J Dermatol; 2005 Jan; 152(1):182-3. PubMed ID: 15656829
    [No Abstract]   [Full Text] [Related]  

  • 54. Polyarteritis nodosa after interferon treatment for chronic hepatitis C.
    de Dios García-Díaz J; García-Sánchez M; Busteros JI; Arcos P
    J Clin Virol; 2005 Feb; 32(2):181-2. PubMed ID: 15653424
    [No Abstract]   [Full Text] [Related]  

  • 55. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
    Lopukhova NL
    Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.
    Gergely AE; Lafarge P; Fouchard-Hubert I; Lunel-Fabiani F
    Hepatology; 2002 May; 35(5):1281-2. PubMed ID: 11981781
    [No Abstract]   [Full Text] [Related]  

  • 57. Uric acid nephrolithiasis associated with interferon and ribavirin treatment of hepatitis C.
    Fontana RJ
    Dig Dis Sci; 2001 Apr; 46(4):920-4. PubMed ID: 11330434
    [No Abstract]   [Full Text] [Related]  

  • 58. Facial hyperpigmentation during pegylated interferon alpha therapy for chronic hepatitis B infection.
    Dag MS; Aydinli M; Kazanci U; Kadayifci A
    Acta Gastroenterol Belg; 2011 Mar; 74(1):103-4. PubMed ID: 21563666
    [No Abstract]   [Full Text] [Related]  

  • 59. Minocycline-induced hyperpigmentation of the tongue.
    Tanzi EL; Hecker MS
    Arch Dermatol; 2000 Mar; 136(3):427-8. PubMed ID: 10724219
    [No Abstract]   [Full Text] [Related]  

  • 60. Hydroxyurea-Induced Oral Hyperpigmentation: A Case Report and Review of the Literature.
    Veillet-Lemay G; Haber RM
    J Cutan Med Surg; 2019; 23(1):111-113. PubMed ID: 30232899
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.